Cerner Receives FDA Clearance for Cerner Bridge Transfusion Administration and Specimen Collections
June 28, 2007
KANSAS CITY, Mo. — June 28, 2007 — Cerner Corp. (Nasdaq: CERN) announced today that Cerner Bridge™ Transfusion Administration and Specimen Collections software solution has received U.S. Food and Drug Administration (FDA) 510(k) pre-market notification clearance. Cerner will immediately make this solution available to clients.
“Obtaining FDA 510(k) clearance for Cerner Bridge Transfusion Administration and Specimen Collections completes the point-of-care suite for Cerner Bridge Medical, which also includes Medication Administration,” said Rick Neece, vice president for Cerner’s Classic Solutions. “This is just another example of Cerner’s commitment to point-of-care solutions and patient safety at the bedside for our clients.”
Cerner Bridge Transfusion Administration and Specimen Collections uses bar-code scanning technology, wireless networks and clinical systems integration to improve patient safety. Utilizing positive patient identification, the solution records and collects information at the bedside and facilitates compliance with standards.
“The Cerner Bridge Transfusion solution provides up to six bar-code checks to ensure the right blood product is being administered to the correct patient. As a result, we feel safer administering blood in our organization,” said Tina Suess, RN, Lancaster General Hospital, who worked with Cerner Bridge Medical as a beta partner. “With a friendly and consistent user interface, our nurses are guided through the transfusion process.”
Cerner Bridge Medical solutions provide healthcare organizations with a full suite of bar-coding solutions for medication administration, specimen collection and blood product administration, ultimately impacting patient safety.
Cerner Corp. is taking the paper chart out of healthcare, eliminating error, variance and waste in the care process. With more than 6,000 clients worldwide, Cerner is the leading supplier of healthcare information technology. The following are trademarks of Cerner: Cerner, Cerner Bridge. NASDAQ: CERN. www.cerner.com.
This release contains forward-looking statements that involve a number of risks and uncertainties. It is important to note that the Company's performance, and actual results, financial condition or business could differ materially from those expressed in such forward-looking statements. The word “will” or the negative of this word, variations thereof or similar expressions are intended to identify such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: changes in the healthcare industry, significant competition, the Company’s proprietary technology may be subjected to infringement claims or may be infringed upon, government regulations, the possibility of product-related liabilities, possible errors or failures in the performance of the Company's software and risks related to third party suppliers. Additional discussion of these and other factors affecting the Company's business is contained in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial condition or business over time.